Direct-to-patient (DTP) programs offer the opportunity to unify the prescription journey from provider to patient. They increase access, decrease friction, and improve trust for the benefit of patients, prescribers, and manufacturers.

Yet, despite the opportunities on offer, in the pharmaceutical world, a historical "wall" exists for high-volume retail products – the cost of traditional distribution. When a product is priced below $50, the math for DTP often seems to stop making sense.

Today, however, the landscape is shifting. Policy changes like Most-Favored Nation (MFN) Pricing are creating new operational requirements for pharmaceutical companies to prove every dollar delivers value. For biopharma leaders who want to remain competitive, redesigning brand support services for scale, efficiency and trust is no longer a "nice to have"––it is a strategic imperative. At the same time, a personalized tech-plus-touch approach is breaking down traditional operational cost barriers. The industry is moving toward a model where access is no longer just about availability––it’s about affordability, efficiency, and auditable integrity.

DTP is a patient-first layer

DTP is a patient-first layer allowing consumers to see the price before they commit, choose how they get their medication and get real-time status updates. Whether the fill goes through commercial insurance, government payors, manufacturer assistance, or MFN-linked cash pricing, DTP acts as an "affordability waterfall." It automatically navigates the split: if a patient is eligible for MFN-mandated cash pricing (via platforms like TrumpRx.gov), the system routes them there; if they have commercial insurance, it seamlessly applies traditional support. This ensures that new pricing mandates don't break the existing commercial experience.

Traditional hubs rely on handoffs, manual processes, and fragmented systems, leading to delays for patients and higher admin burden for prescribers. In contrast, DTP runs on an API-driven foundation anchored to a patient-consented longitudinal record. It is standardized and auditable, allowing manufacturers to measure what matters––promise-date accuracy, delivery time, refill rates, retention, days on therapy, and the satisfaction of both patients and prescribers.

This transformation of the pharmaceutical supply chain benefits every member of the prescription ecosystem – from patients and providers to manufacturers and payers. DTP expands patient access, improves customer satisfaction and helps patients start treatment faster and stay on treatment longer. It allows providers to shed unnecessary administrative work while still maintaining independence. It empowers brand teams to proactively address barriers, optimize outreach and make faster, data-driven decisions that improve adherence and brand performance.

For payors keen to see demonstration of value, DTP provides greater transparency and less waste. Real-time visibility, clear disclosures, auditable routing and standardized experiences reduce rework, increase the likelihood of access success, and help demonstrate there is no steering.

The impact of most-favored nation pricing

Recent legislation changes aim to offer brand-name prescription medications at MFN prices. It is vital that the industry seizes this opportunity in a way which results in genuine savings for patients, increases medication access and secures the future of innovative clinical development.

In this new era of drug pricing, there is a clear imperative and mandate to challenge the pharmaceutical chain status quo and adopt new ways of working. With policymakers demanding proof that every dollar delivers value, DTP allows manufacturers to align resources with outcomes instead of intermediaries’ margins. Rather than applying double discounts on the same prescription, manufacturers can harness dynamic routing which allows them to balance affordability for patients with their own margins. This increases gross-to-net performance without compromising patient experience.

Breaking the operational cost barrier

Digital-first, automated DTP programs are currently supporting products with retail prices as low as $35––far lower than the previous barrier of $50. Making these low-margin, high volume programs viable relies on working smarter rather than just harder.

There are two main changes required to break the operational cost barrier. The first is technology-enabled automation. By automating the heavy lifting of eBI and eBV, and removing manual touchpoints, DTP programs allow volume to scale without the traditional ‘hiring spike’ that usually eats up margins.

The second change is providing an end-to-end coordinated process. Instead of old fragmented systems, the industry needs to embrace a unified patient journey from access to fulfillment and support, enabling a faster, simpler digital pharmacy experience.

A pharmacy model is only as good as its ability to talk to the rest of the healthcare stack. Any successful DTP platform must seamlessly integrate with major EHR systems and telehealth providers via low-friction APIs. It must also offer secure data transfers and real-time routing to ensure the manufacturer never loses visibility.

Instead of the old patchwork of partners needed to complete a patient journey, DTP offers a unified experience. Automated logic determines the best path based on payer rules, AI plus human support helps reduce drop-offs and digital portals offer one-click refills for patients and real-time status dashboards for HCPs. The result? The elimination of cracks in the system for patients to fall through and the ability to deliver DTP at scale – even for low-margin products.

Challenging the status quo

‍In a changing prescription environment, manufacturers need to be ready to challenge the status quo and bring high-volume, low-cost products to the patients who need them most. DTP offers the opportunity to demonstrate ROI, break down traditional operational cost barriers and revolutionize the prescription journey.

The future will belong to those willing to take responsibility for the entire patient pathway––delivering the transparency and traceability that MFN demands, while maintaining the momentum, choice, and value-for-money that patients deserve.‍